BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32974098)

  • 1. Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study.
    Wang HC; Liu PL; Lo PC; Chang YT; Chan LP; Yeh TJ; Hsiao HH; Cho SF
    PeerJ; 2020; 8():e9862. PubMed ID: 32974098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
    Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
    Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
    Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
    Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
    Song Q; Li X; Li B
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
    Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S
    Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors.
    Hobday SB; Brody RM; Kriegsman B; Basu D; Newman J; Cohen RB; Lukens JN; Singh A; D'Avella CA; Sun L
    JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):918-926. PubMed ID: 35980666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
    Depenni R; Cossu Rocca M; Ferrari D; Azzarello G; Baldessari C; Alù M; Nolé F; Codecà C; Boscolo G; Piccininni M; Cavalieri S; Bossi P
    Eur J Cancer; 2019 Jul; 115():4-12. PubMed ID: 31082692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas.
    Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Bourhis J; Deutsch E; Daly-Schveitzer N; Tao Y
    Strahlenther Onkol; 2014 Sep; 190(9):823-31. PubMed ID: 24638267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.
    Kogashiwa Y; Inoue H; Kuba K; Araki R; Yasuda M; Nakahira M; Sugasawa M
    Head Neck; 2018 Nov; 40(11):2424-2431. PubMed ID: 30302873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
    Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
    JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma.
    da Costa AABA; Costa FD; Araújo DV; Camandaroba MPG; de Jesus VHF; Oliveira A; Alves ACF; Stecca C; Machado L; de Oliveira ACF; de Oliveira TB; Nicolau UR; de Lima VCC
    Med Oncol; 2018 Nov; 36(1):8. PubMed ID: 30478503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.
    Bossi P; Bergamini C; Siano M; Cossu Rocca M; Sponghini AP; Favales F; Giannoccaro M; Marchesi E; Cortelazzi B; Perrone F; Pilotti S; Locati LD; Licitra L; Canevari S; De Cecco L
    Clin Cancer Res; 2016 Aug; 22(15):3961-70. PubMed ID: 26920888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
    Tiwari S; Goel V; John MC; Patnaik N; Doval DC
    Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis.
    Hsieh MC; Wang CC; Yang CC; Lien CF; Wang CC; Shih YC; Yeh SA; Hwang TZ
    Biology (Basel); 2021 Oct; 10(10):. PubMed ID: 34681110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa.
    Yang CC; Lien CF; Hwang TZ; Wang CC; Wang CC; Shih YC; Yeh SA; Hsieh MC
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
    Jimeno A; Shirai K; Choi M; Laskin J; Kochenderfer M; Spira A; Cline-Burkhardt V; Winquist E; Hausman D; Walker L; Cohen RB
    Ann Oncol; 2015 Mar; 26(3):556-61. PubMed ID: 25524478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world study of patients with locally advanced HNSCC in the community oncology setting.
    Black CM; Ramakrishnan K; Nadler E; Tseng WY; Wentworth C; Murphy J; Fulcher N; Wang L; Alexander M; Patton G
    Front Oncol; 2023; 13():1155893. PubMed ID: 37664029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.